Onconova Therapeutics Inc. (NASDAQ:ONTX) went down by -7.85% from its latest closing price compared to the recent 1-year high of $1.93. The company’s stock price has collected -13.90% of loss in the last five trading sessions. Press Release reported on 04/22/21 that Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
Is It Worth Investing in Onconova Therapeutics Inc. (NASDAQ :ONTX) Right Now?
Plus, the 36-month beta value for ONTX is at 1.60. Opinions of the stock are interesting as 1 analysts out of 2 who provided ratings for Onconova Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $2.10. ONTX currently public float of 221.88M and currently shorts hold a 2.71% ratio of that float. Today, the average trading volume of ONTX was 41.89M shares.
ONTX’s Market Performance
ONTX stocks went down by -13.90% for the week, with a monthly drop of -30.13% and a quarterly performance of -2.36%, while its annual performance rate touched 115.61%. The volatility ratio for the week stands at 8.44% while the volatility levels for the past 30 days are set at 9.62% for Onconova Therapeutics Inc.. The simple moving average for the period of the last 20 days is -9.95% for ONTX stocks with a simple moving average of -0.50% for the last 200 days.
Analysts’ Opinion of ONTX
Many brokerage firms have already submitted their reports for ONTX stocks, with H.C. Wainwright repeating the rating for ONTX by listing it as a “Buy.” The predicted price for ONTX in the upcoming period, according to H.C. Wainwright is $7.50 based on the research report published on March 01st of the previous year 2018.
H.C. Wainwright gave a rating of “Buy” to ONTX, setting the target price at $6 in the report published on October 09th of the previous year.
ONTX Trading at -33.09% from the 50-Day Moving Average
After a stumble in the market that brought ONTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.65% of loss for the given period.
Volatility was left at 9.62%, however, over the last 30 days, the volatility rate increased by 8.44%, as shares sank -25.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -59.45% lower at present.
During the last 5 trading sessions, ONTX fell by -13.90%, which changed the moving average for the period of 200-days by -2.01% in comparison to the 20-day moving average, which settled at $0.7248. In addition, Onconova Therapeutics Inc. saw 42.34% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ONTX starting from OLER ABRAHAM N., who purchase 12,000 shares at the price of $1.00 back on Feb 16. After this action, OLER ABRAHAM N. now owns 152,000 shares of Onconova Therapeutics Inc., valued at $12,000 using the latest closing price.
Guerin Mark Patrick, the Chief Financial Officer of Onconova Therapeutics Inc., purchase 15,000 shares at $1.00 during a trade that took place back on Feb 16, which means that Guerin Mark Patrick is holding 145,213 shares at $15,000 based on the most recent closing price.
Stock Fundamentals for ONTX
Current profitability levels for the company are sitting at:
- -10819.48 for the present operating margin
The net margin for Onconova Therapeutics Inc. stands at -10890.48. The total capital return value is set at -281.63, while invested capital returns managed to touch -283.48. Equity return is now at value -181.70, with -95.40 for asset returns.
The receivables turnover for the company is 3.42 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.97.